Bryn Pharma Raises $11 Million in Financing to Advance Bi-Dose Epinephrine Nasal Spray for Anaphylaxis


RALEIGH, N.C., Aug. 4, 2020 /PRNewswire/ -- Bryn Pharma, LLC ("Bryn" or the "Company"), a privately held pharmaceutical company dedicated to finding a better way for patients and caregivers to treat anaphylaxis, today announced that it has raised an additional $11 million in financing to fund the remaining development and regulatory approval activities, and pre-launch commercialization program for BRYN-NDS1C, its bi-dose epinephrine nasal spray. The financing was an extension of the financing transaction completed by the Company in October 2019 and brings the total proceeds from the transaction to $26 million. This was the fourth financing series completed by the Company. Participants included existing and new investors comprised of investment funds, family offices and private investors.

"This financing provides us further resources to continue building the value of Bryn Pharma and to bring our disruptive nasal epinephrine product to the large number of patients requiring protection from anaphylactic events," said David Dworaczyk, Ph.D., CEO of Bryn Pharma. "We are pleased with the enthusiastic response to this offering and to the continued support of investors as we forge ahead with this important initiative for anaphylactic patients."

BRYN-NDS1C Bi-Dose Epinephrine Nasal Spray
Bryn Pharma's Bi-dose Epinephrine Nasal Spray (BRYN-NDS1C) is a single, portable, needle-free device capable of delivering two therapeutic doses of epinephrine, replacing the need to carry two epinephrine auto-injectors. In early 2019, the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to BRYN-NDS1C. The human clinical trial program designed to support U.S. approval to market the product candidate is currently underway. In April 2020, results of the latest human clinical trial were presented at the American Academy of Asthma, Allergy and Immunology (AAAAI) Annual Meeting and demonstrated that intranasal (IN) delivery of epinephrine from the Company's needle-free, bi-dose device was comparable to intramuscular (IM) injection in pharmacokinetics, pharmacodynamics and safety. BRYN-NDS1C is not currently approved for sale by the FDA or any international regulatory authority.

About Anaphylaxis
Anaphylaxis is a serious, life-threatening allergic reaction. The most common anaphylactic reactions are to foods, insect stings, medication and latex.1 A major difference between anaphylaxis and other allergic reactions is that anaphylaxis typically involves more than one system of the body.2 Anaphylaxis requires immediate medical treatment, driving approximately 100,000 emergency room visits in the U.S. each year.1,3 Because 30% of patients who develop anaphylaxis will require a second dose of epinephrine to control symptoms, practice parameters recommend that physicians provide patients with two auto-injectors.4 If not treated properly, anaphylaxis can be fatal.2 However, studies have shown that the majority of people at risk for anaphylaxis often do not carry two epinephrine auto-injectors due in part to size and cost of the products, putting patients at greater risk of severe complications during an allergic reaction.

About Bryn Pharma
Bryn Pharma, founded in 2016, is a privately held pharmaceutical company founded by patients for patients. Bryn is focused on positively disrupting the existing market for epinephrine auto-injectors by delivering an accessible, easy-to-use alternative that better meets the needs of patients. Bryn Pharma seeks to provide this growing population at risk for anaphylaxis with A Better Way to be prepared for a life-threatening allergic reaction. For more information visit

Forward Looking Statements
Statements made in this press release that look forward in time or that express beliefs, expectations or hopes regarding future occurrences or anticipated outcomes or benefits are forward- looking statements. A number of risks and uncertainties, such as risks related to product development and commercialization efforts, results of clinical trials, ultimate clinical outcomes and benefit of the Company's products to patients, market and physician acceptance of the Company's products, intellectual property protection and competitive product offerings, could cause actual events to differ from the expectations indicated in these forward-looking statements. You are cautioned not to put any undue reliance on any forward-looking statement. This press release is neither an offer to sell nor a solicitation of an offer to purchase any particular securities. Any such offer or solicitation will be made only pursuant to definitive legal agreements prepared specifically for such purpose. An investment in the Company's securities entails significant risks and is suitable only for sophisticated investors who can afford a loss of their entire investment; no assurance can be given that investment objectives will be achieved. In considering the performance information contained herein, you should bear in mind that past performance is not necessarily indicative of future results; there can be no assurance that the Company will achieve comparable results or that any projected returns will be met. The Company does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.



American Academy of Allergy, Asthma & Immunology. Available at Accessed on July 31, 2020.


American Academy of Allergy, Asthma & Immunology. Available at: Accessed on July 31, 2020.


Fromer L. Prevention of Anaphylaxis: The Role of the Epinephrine Auto-Injector. Am J Med. 2016 Dec; 129(12): 1244-1250.


Anaphylaxis –a practice parameter update 2015; Lieberman, Phillip et al.; Annals of Allergy, Asthma & Immunology, Volume 115, Issue 5, 341-384



Cision View original content to download multimedia:

SOURCE Bryn Pharma, LLC


Back to news